The EU Commission’s latest intervention confirms that pharmaceutical disparagement remains a key enforcement priority under Article 102 TFEU. Following Vifor and Teva Copaxone, the Sanofi case highlights the competition concerns that may arise where promotional practices influence healthcare professionals’ choices in a misleading way and hinder the uptake of competing medicines.
The latest Newsflash prepared by our member firm Kyriakides Georgopoulos Law Firm looks at the Commission’s concerns, the commitments offered by Sanofi and the broader implications for pharmaceutical companies’ promotional practices.